CPRX News and Press, Catalyst Pharmaceuticals Inc. From 11/10/22

Catalyst Pharmaceuticals, Inc. (CPRX) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Ali Grande - Chief Financial Officer Patrick McEnany - Chairman and Chief Executive Officer Jeffrey Del Carmen - Chief Commercial Officer ...

Catalyst Pharmaceuticals press release ( NASDAQ: CPRX ): Q3 Non-GAAP EPS of $0.26 beats by $0.07 . Revenue of $57.24M (+59.2% Y/Y) beats by $3.55M . FY2022 Guidance : The company has increased its forecast for total revenues to be in the range of betwe...

Achieved Record Q3 2022 FIRDAPSE® Net Revenue of $57.2 Million, a 59.3% YoY Increase Company Increases Full Year 2022 Total Revenue Guidance to $205-210 Million Q3 2022 GAAP Net Income of $22.7 Million ($0.22 per basic and $0.20 per diluted share), which Includes a ...

CORAL GABLES, Fla., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announce...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips For investors looking for the best stocks to buy on a dip, “the dip” can mean a lot of different things. It can be the case of a market dominator that is trading near its low following a brutal bear market. Or...

CORAL GABLES, Fla., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announce...

The market may be down 23% this year, but that hasn't stopped a trio of drug companies from powering onward. Vertex Pharmaceuticals , (NASDAQ: VRTX) Catalyst Pharmaceuticals , (NASDAQ: CPRX) and Corcept Therapeutics (NASDAQ: CORT) are all rising sharply in contrast t...

CORAL GABLES, Fla., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announc...

Have you ever experienced sticker shock when looking at a stock? If so, it was probably for something like Berkshire Hathaway (NYSE: BRK.A) , with an eye-popping price of $419,020 per share. Thankfully, there are much cheaper companies to buy, and some of them might even grow a bit ...

Multiple insider sales have hurt commercial-stage biotech Catalyst Pharmaceuticals ( NASDAQ: CPRX ) as the company became a notable decliner in the pre-market trading Friday with a drop of ~7% . The sellers include CPRX, co-founder, President, and Chief Executive Patri...